H.C. Wainwright notes that Assembly Biosciences (ASMB) announced an interim safety, pharmacokinetics and efficacy dataset from an ongoing Phase 1b study of ABI-4334 in patients with chronic hepatitis B virus infection, which includes results from the first 150 mg cohort, along with interim safety data from the second cohort. The firm maintains a Neutral rating on Assembly shares as the analyst is “currently uncertain” on the efficacy of Assembly’s programs including ABI-5366, ABI-4334, and ABI-6250, the firm noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
- Assembly Biosciences announces interim PK, efficacy from Phase 1b study
- Assembly Biosciences announces $30.1M investment, funding from Gilead
- Assembly Biosciences Reports Q3 2024 Financials and Strategic Advances
- Assembly Biosciences reports Q3 EPS ($1.51), consensus ($2.02)
- Is ASMB a Buy, Before Earnings?